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PERCH Site ReSultS
Abstract: The Pneumonia Etiology Research for Child Health (PERCH) 
study evaluated the etiology of severe and very severe pneumonia in chil-
dren hospitalized in 7 African and Asian countries. Here, we summarize 
the highlights of in-depth site-specific etiology analyses published sepa-
rately in this issue, including how etiology varies by age, mortality status, 
malnutrition, severity, HIV status, and more. These site-specific results 
impart important lessons that can inform disease control policy implica-
tions.
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(Pediatr Infect Dis J 2021;40:S1–S6)
The Pneumonia Etiology Research for Child Health (PERCH) study was the largest, most comprehensive pneumonia etiol-
ogy study conducted in over 3 decades.1 Its aim was to estimate 
the etiologic fraction of pneumonia occurring in settings where 
child mortality from pneumonia is still far too high. This evidence 
could be used to guide clinicians, governments, donors and vac-
cine developers and to inform treatment and prevention strategies. 
Over 2 consecutive years at each site (between 2011 and 2014) in 
7 countries in Africa and Asia (The Gambia, Mali, Zambia, South 
Africa, Kenya, Bangladesh and Thailand), the PERCH study team 
enrolled 4232 children 1–59 months of age who were hospitalized 
with severe pneumonia and 5325 control children from the same 
communities who did not have severe pneumonia. Children were 
tested for over 30 potential pathogens in multiple specimens, and 
using a Bayesian, partial latent class analysis, we estimated prob-
abilities of etiologic agents (ie, etiologic fraction) at the individual 
and population level.1
The overall findings among HIV-uninfected children in 
PERCH, published previously, estimated that 61% of severe pneu-
monia cases were caused by viruses; respiratory syncytial virus 
A/B (RSV) alone accounted for 31% of cases.1 That publication 
included some, but limited, site-specific etiology results. Those 
results also excluded children living with HIV. Although viruses, 
especially RSV, were estimated to be the dominant cause at all 7 
sites, the sites were heterogeneous in their settings and in the char-
acterization of the children with severe/very severe pneumonia they 
enrolled (Tables 1 and 2). In this special issue, site-specific etiology 
was explored in more depth, stratified by factors such as age, mor-
tality, malnutrition, severity, HIV status and more. Selected site-
specific results contained in this special issue are highlighted in 
Table 2. Key findings across the 9 site-specific reports (2 each from 
Zambia and South Africa) include:
• Etiologic results for the full list of pathogens at each site: Pre-
viously published PERCH results described site-specific etiol-
ogy caused by 10 of the over 30 pathogens evaluated; for some 
sites, such as Thailand,10 those pathogens accounted for only 
about half of the attributed etiology.
• Effects of age and severity are examined in more depth: Dif-
ferences are revealed between sites; for example, the etiologic 
fraction of pneumonia attributed to RSV was higher in chil-
dren <1 year than 1–4 years at all sites except Zambia5 where 
the etiologic fraction was similarly high in both age groups.
• Etiology of pneumonia in children living with HIV are shown 
for the first time: Two sites, South Africa8 and Zambia,6 had 
relatively high prevalence of HIV in their hospitalized cases 
(12% and 17%). Bacteremia and in-hospital death were fre-
quent among children with HIV at both sites. Bacterial and 
fungal pathogens, including Pneumocystis jirovecii, Strepto-
coccus pneumoniae, Staphylococcus aureus, contributed a 
considerable burden of radiologically confirmed pneumonia 
in cases at both sites.
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• Etiology of pneumonia in HIV-exposed but uninfected 
(HEU): Children whose mothers were living with HIV but 
who were themselves uninfected are examined in South 
Africa7 and Zambia5 and compared with children whose 
mothers did not have HIV. In Zambia, mortality among 
HEU cases was nearly double that of HIV-unexposed 
cases. Etiology results differed between the 2 sites: in 
South Africa, the etiology was similar between HEU- and 
HIV-unexposed pneumonia cases, while in Zambia, etiol-
ogy among HEU cases shared features of children with 
HIV and unexposed.
• Etiology by mortality status: While RSV was the most com-
mon cause of severe pneumonia overall, bacteria and fungi 
were more common than RSV as the cause among cases who 
died. Mali3 and Zambia5 had the highest case fatality ratios 
among PERCH sites and were a focus of etiology evalua-
tion among the fatal cases. In Mali, S. aureus, P. jirovecii and 
Haemophilus influenzae type b together accounted for 40% of 
fatal cases (compared with only 6.9% of those who survived), 
while RSV, human metapneumovirus (HMPV) and parainflu-
enza virus (PIV) type 3 together comprised 6.5% (compared 
with 48% of cases who survived). In Zambia, most (46%) 
fatal cases were caused by H. influenzae type b, S. aureus, P. 
jirovecii and other fungi, compared with 5.1% among cases 
that survived, while RSV, rhinovirus and HMPV caused 3.6% 
of pneumonia in fatal cases compared with 47% among cases 
that survived.
• Clinical characteristics associated with mortality: In Zam-
bia,5 fatal pneumonia cases were more likely to have a longer 
illness duration before admission, more severe disease, HIV 
exposure and to be malnourished.
• Role of comorbidities in mortality: The frequency and influ-
ence of comorbidities in cases from Thailand10 was explored 
and found to be comparable with that at the other PERCH 
sites. Comorbidities were an important contributing factor 
to fatalities at all sites. In Thailand, 78% of fatal cases had 
a comorbidity, primarily a developmental delay; comorbidi-
ties were present in 44% of cases that died in The Gambia2 
and Zambia5 and in 67%–80% of those who died in Mali,3 
Kenya4 and Bangladesh.9 In Mali, moderate to severe wast-
ing and stunting were associated with an increased likeli-
hood of a bacterial etiology and increased the likelihood of 
a fatal outcome.
• Role of malnutrition on etiology: Pneumonia in severely mal-
nourished cases, explored in children from Mali,3 was propor-
tionally much less frequently attributed to RSV and HMPV 
compared with other children (combined 15% vs. 42% for 
weight-for-height <−2 SD and 7.2% vs. 40% for height-for-age 
Z scores <−2 SD). The probability of H. influenzae (21% vs. 
2.9%), S. aureus (14% vs. 2.6%) and Mycobacterium tubercu-
losis (6.9% vs. 0.5%) was substantially more common in cases 
with low weight-for-height Z scores than in cases with higher 
Z scores. The etiology of pneumonia in severely malnourished 
cases was more evenly distributed across pathogens but perhaps 
with more bacterial than viral pathogens as the most common 
causes; for children with height-for-age Z scores <−2 SD, the 
leading causes were S. pneumoniae (11%) and H. influenzae 
(9.7%).
• Findings from lung aspirates are compared with pre-Hib vac-
cine and pre-PCV time periods: In The Gambia2 where there 
was substantial prior experience collecting lung aspirate sam-
ples, H. influenzae type b (n = 1) was seen less during PERCH 
TABLE 1. Characteristics of PERCH Sites and Enrolled Cases
Country Site Urban/Rural
Time between Vaccine 
Introduction and PERCH 
Enrollment
Number  
of Cases  
Enrolled*


























Basse Rural 15 years 2 years 631 63 15 7.8 32 47 4.3 S7–S17
Mali Bamako Urban 5 years 1 year 653 68 52 47 18 47 16 S18–S28
Kenya Kilifi Rural 10 years 6 months 630 54 51 30 13 50 5.9 S29–S39





78 31 36 12 57  16 S40–S49
HIV-positive: 
103
75 35 60 5.8 87  42 S50–S58
South  
Africa
Soweto Urban 12 years 2.5 years HIV-uninfected:
805
75 32 75 34 64 3.0 S59–S68
HIV- positive: 
115
72 34 78 15 88 19 S69–S78







N/A N/A║ 223 39 23 24 46 50 4.0 S91–S100
*Restricted to HIV-uninfected cases at all sites except Zambia and South Africa where the number of HIV-uninfected and HIV-infected cases is reported separately.
†Very severe pneumonia defined as cough or difficulty breathing and at least 1 of the following signs: central cyanosis, difficulty breast-feeding or drinking, vomiting everything, 
convulsions, lethargy, unconsciousness or head nodding.
‡Hypoxemia defined as arterial oxygen saturation <92% on room air (<90% for sites at elevation: Zambia and South Africa) or a requirement for supplemental oxygen on admis-
sion if a room air reading was not available; a room air oxygen saturation reading was available for 3514 (88%) children; the South African site was at an altitude of 1600 meters 
above sea level and had a standard clinical practice to administer supplemental oxygen for all children admitted to hospital with a diagnosis of severe or very severe pneumonia.
§CXR positive defined as consolidation and/or other infiltrate. Restricted to interpretable chest radiographs.
¶Died in hospital or postdischarge but within 30 days of admission.
║N/A: PCV not in use by national immunization program during PERCH study.
CXR indicates chest radiograph; N/A, not applicable; PERCH, Pneumonia Etiology Research for Child Health; Hib, Haemophilus influenzae type b vaccine; PCV, pneumococcal 
conjugate vaccine.
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TABLE 2. Features of PERCH Study Sites and Highlights of Site-specific Findings
Site Highlights
The Gambia2 •  Low proportion of cases were exposed to antibiotics before specimen collection (10%).
Setting:
Low GDP per capita, rural, a 
high child mortality rate, 
seasonal malaria transmis-
sion and a low HIV infection 
prevalence.
•  Amongst controls 1 year of age or older, 93% were fully vaccinated for age against Haemophilus influenzae and 80% 
against S. pneumoniae.
•  Positive blood cultures were observed in 14 (5%) of CXR-positive cases: 7 (50%) were S. pneumoniae (n = 2 PCV13 
serotypes and n = 5 non-PCV13 serotypes), 2 were H. influenzae nontype b and the remaining were single occur-
rences of other pathogens.
•  Lung aspirates were available from 21 CXR-positive cases (most of any site) with S. pneumoniae, Moraxella 
catarrhalis, and H. influenzae being the most commonly detected pathogens.
•  Amongst CXR-positive cases, RSV (37%) and S. pneumoniae (13%) were the leading causes, followed by parainflu-
enza viruses (9.2%), Mycobacterium tuberculosis (8.3%) and H. influenzae (4.7%), with viruses accounting for 58% of 
cases and bacteria 28%. However, in CXR-positive very severe pneumonia cases, bacterial causes dominated (77%) 
with S. pneumoniae (41%) being the leading cause.
•  Epidemic pathogens such as parainfluenza viruses, notably Types 1 and 3, featured strongly.
Mali3
Setting:
Low GDP per capita, high-
density urban, high child 
mortality rate, seasonal 
malaria transmission, low 
HIV infection prevalence, 
well-established Hib vaccine 
program, PCV introduced <1 
year before start of the study.
•  The case fatality was high (13%) and etiology differed between fatal and nonfatal cases, with more bacteria and 
fungi among fatal cases: Staphylococcus aureus, Pneumocystis jirovecii, and H. influenzae type b together accounted 
for 39% of fatal cases compared with only 6.9% of those who survived, while RSV, HMPV and PIV-3 together com-
prised 6.5% of fatal cases compared with 48% of cases who survived.
•  Pneumonia in malnourished children was less frequently caused by RSV and HMPV compared with other children 
(combined 15% vs. 42% for weight-for-height and 7.2% vs. 40% for height-for-age), and instead was more commonly 
caused by bacteria. The top causes in malnourished children with weight-for-height Z scores below −2 SD were H. 
influenzae (21%), S. aureus (14%) and S. pneumoniae (12%).
•  Despite parental report that at least 60% of CXR+ cases were vaccinated with both PCV and Hib vaccines, most 
positive blood cultures (n = 12) were vaccine-preventable serotypes: 3 of 6 S. pneumoniae were PCV13-type (6B, 19A 
and 23F), 4 of 5 H. influenzae were type b, and 1 was positive for nontyphoidal Salmonella spp.
•  No culture isolates were recovered from 9 lung aspirates.
Kenya4 •  Viruses accounted for 77% of the attribution of CXR-positive pneumonia. RSV was the main cause of CXR-positive 
pneumonia, followed by rhinovirus. The small contribution of Hib and pneumococcus to pneumonia may reflect the 
impact of vaccine introductions in this population.
Setting:
Predominantly rural, low HIV 
prevalence, mature Hib vaccine 
program and recent PCV 
program introduced with catch-up 
campaign strategies for all 
children under 5 years. Endemic 
malaria but transmission 
declining over past 15 years.
•  Evaluated discharge diagnoses (not done at other sites): 28% of PERCH cases were not assigned LRTI in either their 
primary or secondary discharge diagnosis. The percentage without an LRTI diagnosis was higher for very severe 
pneumonia (42%) than for severe pneumonia (14%). Some (20%) of non-LRTI diagnosed cases had CXR abnormali-
ties consistent with pneumonia. Some non-LRTI diagnoses included clinical presentations that can co-occur with 
pneumonia (e.g., malnutrition, malaria, anemia, febrile convulsions, pulmonary TB, immunosuppression, sepsis, 




lated, urban population with 
high HIV and M. tuberculosis 
prevalence and limited access 
to high-quality health care. 
Hib vaccine widely available 
but PCV not introduced until 
3 months before the end of 
the study. Study conducted at 
a referral facility with most 
children receiving antibiotics 
before enrollment.
•  Mortality among HIV-uninfected children was high (16%) and was higher among HIV-exposed (21%) compared with 
unexposed (11%) children. Outcomes were poor for HIV-infected children, with 40% dying in hospital.
•  Etiology among HIV-uninfected was highest for RSV (26%), M. tuberculosis (13%) and HMPV (13%). In contrast, for 
HIV-infected children, RSV contributed to only 3.7% of CXR-positive cases while bacterial and fungal pathogens 
accounted for over 75%: S. pneumoniae (20%), S. aureus (13%), P. jirovecii (25%) and M. tuberculosis (4.5%).
•  In Zambia, no difference in RSV etiologic fraction was seen by age. By contrast at all other sites, the proportion of 
pneumonia due to RSV in HIV-uninfected cases was higher in children <1 year of age. RSV contributed relatively 
little to the pneumonia mortality.
•  Among fatal HIV-uninfected cases, most (46%) were caused by H. influenzae type b, S. aureus, P. jirovecii and fungi, 
compared with 5.1% among cases that survived, while RSV, rhinovirus and HMPV caused only 3.6% of pneumonia 
in fatal cases compared with 47% among cases that survived.
•  Despite only a handful of children enrolled at the end of the study being fully immunized with PCV10 in Zambia, 
disease due to PCV10-type S. pneumoniae was rare (1.7%). However, lack of detection may in part be due to the 
near-universal practice of giving 1 dose of antibiotic before referral to the PERCH study facility—approximately 
90% received antibiotics before admission. Despite this, among HIV-uninfected children, CXR-positive pneumonia 
was caused by treatable organisms in a large (38%) portion of cases. Potentially treatable causes of pneumonia 
accounted for 6 of the top 10 pathogens.
•  Pediatric M. tuberculosis is a significant cause of pneumonia for hospitalized children, both HIV-infected and unin-
fected.
•  Assessment of HIV-related care and treatment of HIV-infected cases occurring before admission revealed that only 
35% had been receiving prophylactic co-trimoxazole, 14% had received anti-retroviral therapy and only 37% of 
caregivers knew their child’s HIV status at time of enrollment.
•  Fatal HIV-uninfected pneumonia cases were more likely to be malnourished (62% vs. 26%), be HIV-exposed (38% 
vs. 24%), sleep with 4 or more people in the same room (29% vs. 14%) and they waited longer before coming to the 
hospital (>5 days ill: 35% vs. 19%). Their pneumonia was more severe at admission: any danger sign (59% vs. 26%), 
lethargy (42% vs. 7.3%), hypoxia (60% vs. 32%) and many other clinical and laboratory differences.
South Africa7,8 •  Results are presented for both children living with and without HIV, including stratified by HIV-exposure status 
among HIV-uninfected children. Pneumonia etiology among children with HIV was proportionally less commonly 
attributed to viral pathogens (27%) than among HIV-exposed uninfected (50%) and HIV-unexposed (58%) children. 
Among children with HIV, P. jirovecii, S. aureus, S. pneumoniae and RSV were the most common causes; P. jirovecii 
and RSV featured almost exclusively amongst children <12 months. There was limited attribution to cytomegalovi-
rus as a cause of pneumonia in the children with HIV.
Setting:
Low-middle income sub-
Saharan African setting 
with established vaccination 
programs against Hib and 
pneumococcus as well as a 
high HIV and tuberculosis 
burden.
•  Bacteremia (6.7%) and in-hospital death (10%) were frequent amongst children living with HIV who had radiologi-
cally confirmed disease. Clinical and laboratory characteristics of fatal cases are presented.
•  M. tuberculosis was commonly attributed (9.7%) as the cause of pneumonia in HIV-uninfected children.
•  The impact of sensitivity for detecting M. tuberculosis in a high burden setting is evaluated since more intensive 
screening was conducted at this site and the impact on etiologic conclusions is explored.
(Continued)
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compared with earlier studies but PCV-type pneumococcus 
was still observed during this early PCV use period (PCV 
was introduced 2 years prior to PERCH), reinforcing the need 
for ongoing monitoring through surveillance. S. pneumoniae, 
Moraxella catarrhalis and H. influenzae were the only patho-
gens detected in lung aspirates of Gambian cases.
• PERCH severe pneumonia etiology is considered in the con-
text of surveillance data: The magnitude of severe pneumonia 
attributed to influenza and pneumococcus was smaller than 
expected. PERCH did not find evidence that influenza virus 
caused a large portion of the pneumonias during the study 
period. Local surveillance data on influenza and other sea-
sonal pathogens support the low influenza prevalence in cases 
and controls during the period of the PERCH study, notwith-
standing that some sites have reported pneumonia associated 
with influenza in periods before and after the PERCH study. 
Bangladesh9 and Thailand10 did not detect any pneumococ-
cal positive blood cultures during PERCH, but studies of less 
severe respiratory illness and bloodstream infections at those 
sites demonstrate that pneumococcal disease was present dur-
ing the PERCH enrollment period. Potential explanations are 
explored for the lack of pneumococcal disease detection in 
PERCH cases in these settings where pneumococcal conju-
gate vaccine was not in use.
• Specificity of the PERCH severe and very severe pneumonia 
case definition: PERCH used the WHO-defined severe or 
very severe pneumonia case definition, which is designed to 
favor sensitivity at the expense of specificity. The Kenya4 site 
explored the specificity of the case definition by examining 
the primary hospital-assigned discharge diagnoses among all 
admissions and among PERCH cases. Lower respiratory tract 
infection (LRTI) was recorded more often as a primary dis-
charge diagnosis in PERCH enrollees (66%) than in all admis-
sions (25%), but 28% of PERCH cases were not assigned 
LRTI in either primary or secondary discharge diagnoses. 
The proportion of cases without LRTI listed as a discharge 
diagnosis was higher for those with PERCH-defined very 
severe pneumonia (42%) than for severe pneumonia (14%). 
However, hospital-assigned diagnosis is not a gold standard, 
as shown by the fact that 15% of CXR-positive cases did not 
have a discharge diagnosis of LRTI.
• Impact of repeat M. tuberculosis testing in a high prevalence 
setting: Assumptions were required in the PERCH etiology 
analysis regarding the sensitivity for all pathogen/specimen 
tests conducted, including for M. tuberculosis. South Africa7 
performed multiple M. tuberculosis tests on individual cases 
over several days while other sites tested only once, on the day 
of admission. The South Africa site reestimated the fraction 
of pneumonia attributed to M. tuberculosis using any positive 
test and increased sensitivity to account for this from the range 
of 10%–30% to 20%–50%. The result was a change in the 
estimated proportion attributed to M. tuberculosis from 6.4% 
to 9.7%.
This collection of results is part of a suite of papers1,11 and 
should be taken in that context. The results represent sites with 
diverse epidemiologic settings, including 2 geographic regions, dif-
ferences in altitude, a range of low- and middle-income economic 
backgrounds, urban and rural communities, variations in HIV and 
malaria prevalence and variations in PCV and Hib vaccine use. Each 
of these factors likely contributes to variations in the etiologic spec-
trum and mortality of pneumonia in children. While a study like 
PERCH can provide important insights, it does not take the place 
of routine ongoing surveillance, which should continue, especially 
following new vaccine introduction. Equally important, our data are 
population data and cannot be extrapolated to the individual patient 
as an etiologic probability diagnosis. Particularly for the viruses, 
those that appear to be of greatest public health importance will 
likely require improved rapid or bedside diagnostics for individual 
patient diagnosis, as well as routine monitoring for prioritization for 
future therapeutic or preventive measures. Finally, PERCH was a 
study of severe and very severe childhood pneumonia, but its find-
ings have relevance to all grades of childhood pneumonia severity 
in that, irrespective of primary etiology, given the prominence of 
bacterial infection in mortality, appropriate antimicrobial therapy 
early in infection likely remains important in reducing the overall 
pneumonia case fatality rate, and should continue.
In conclusion, these site-specific results impart 5 important 
lessons that have disease control policy implications.
1. Even though bacteria still account for many childhood pneumo-
nia deaths, bacteria no longer account for the majority of pneu-
monia deaths as in past decades; most cases of severe and very 
Bangladesh9 •  The clinical manifestations of the pneumonia syndrome were different from that at the other sites, with the major-
ity of cases having crackles (93%) and wheeze (97%), and very few with very severe pneumonia (11%).Setting:
Low HIV-seroprevalence 
and low seasonal malaria 
transmission. Hib introduced 
in 2009. PCV introduced 
after PERCH. Few children 
exposed to antibiotics before 
specimen collection.
•  Only 3 cases were blood culture positive, all Enterobacteriaceae, despite only 20% with evidence of antibiotics before 
admission. Although no cases were blood culture positive for Streptococcus pneumoniae, positives were detected at 
normal background rates among PERCH-ineligible children during the same time period.
•  No organisms were recovered from the 4 lung aspirates collected.
•  Detection of influenza was rare in PERCH cases and controls; surveillance systems operating during PERCH con-
firmed no substantial circulation of influenza was detected.
•  Most etiology was attributed to viruses (78%), driven primarily by RSV (31%) and rhinovirus (23%). There was 
limited evidence for influenza or S. pneumoniae.
•  Only minor differences were seen between urban and rural settings.
Thailand10 •  RSV and M. tuberculosis accounted for 35% and 10%, respectively, of the total etiologic fraction of CXR-positive 
cases.
•  No pneumococci were identified on culture despite lack of PCV use in the national immunization program. Other 
research shows invasive pneumococcal disease is not uncommon in Thailand. It may not have been detected in 
the PERCH study due to prior treatment with antibiotics, either because antibiotics reduce culture sensitivity or 
because they prevent progression to severe pneumonia.
Setting:
Middle income setting, no Hib or 
PCV use
•  Comorbidities, primarily developmental delay, were an important contributing factor to fatalities.
Hib indicates Haemophilus influenzae type b vaccine; PCV, pneumococcal conjugate vaccine; PERCH, Pneumonia Etiology Research for Child Health; RSV, respiratory syncytial 
virus; CXR, Chest radiograph; LRTI, Lower respiratory tract infection; HMPV, human metapneumovirus; PIV-3, parainfluenza virus type 3.
TABLE 2. (Continued.)
Site Key Features
The Pediatric Infectious Disease Journal • Volume 40, Number 9S, September 2021 PERCH Site-specific Etiology Results
© 2021 The Author(s). Published by Wolters Kluwer Health, Inc. www.pidj.com | S5
severe pneumonia are viral, and thus primary prevention poli-
cies could be adapted accordingly.
2. A corollary to the point above is that many childhood pneu-
monia cases involve codetection of multiple pathogens, which 
could indicate coinfection amongst 2 or more of these. Our sta-
tistical model required single pathogen etiologic assignment to 
create a pie chart of all identified infecting agents. It was not 
intended to rule in or out coinfection. Multiple studies using 
both animal models and human epidemiologic data have identi-
fied coinfection, notably sequential viral–bacterial coinfection, 
as a contributor to very severe pneumonia and pneumonia mor-
tality. The role of co-detected pathogens, whether one or both 
caused the pneumonia, deserves further investigation using a 
different study design than was used in PERCH.
3. Although the leading pathogens were common to all sites, we 
observed substantial variation in etiologic fraction by site, even 
on the same continent, which will affect disease control priori-
ties, policies and even clinical practices. To further reduce child 
pneumonia mortality, control policies will need local/regional 
adaptation.
4. Within countries, there may be differences in relative pathogen 
prevalence between urban and rural settings that could affect 
clinical management, and therefore health policies and services 
may need to be correspondingly adapted. For example, HIV 
prevalence, and therefore M. tuberculosis and P. jirovecii preva-
lence, may be higher in population-dense urban settings than in 
rural settings, and therefore the etiologic fraction of all pneumo-
nia due to these pathogens would be higher in urban versus rural 
health facilities. Local data will assist in adjusting health policy 
and practices accordingly.
5. Young age and comorbidities including malnutrition, small for 
gestational age and HIV-infection and exposure, increase the 
likelihood of mortality from childhood pneumonia and affect 
the fraction attributed to bacteria—epidemiologic findings that 
can inform disease control policies and practices.
We would like to thank the communities that voluntarily 
participated in these studies, not simply for their cooperation, but 
for the knowledge that they have contributed, which will benefit 
children worldwide, many not yet born, for years to come.
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